Vaccines
COVAX
India’s export ban on COVID-19 shots risks dragging the battle against the pandemic “back to square one” unless wealthy nations step in to plug a gaping hole in the COVAX global vaccine-sharing scheme, health specialists said on Thursday.
COVAX, which is critical for poorer countries, relies on AstraZeneca shots made by the Serum Institute of India, the world’s biggest maker of vaccines. It was already around 100 million doses short of where it had planned to be when India halted exports a month ago amid a surge in infections there.
AstraZeneca
Two doses of the Oxford/AstraZeneca COVID-19 vaccine may be around 85 percent to 90 percent effective against symptomatic disease, Public Health England (PHE) said on Thursday, while cautioning that it did not yet have enough data to be conclusive.
“This latest real-world data from PHE adds to the growing body of evidence…
